ADVANCED SOLID TUMORS

This early-phase study tested a new drug called BAY 2862789 in 45 people with advanced solid tumors, including a type of lung cancer. The drug works by activating the body's immune T-cells to fight cancer. The main goals were to check safety, find the best dose, and see how the d…

This early-phase study tested an experimental drug called SHR-A1811 in 396 adults with advanced solid tumors that have a specific marker (HER2). The main goal was to check safety and how the drug moves through the body. Researchers also looked for signs that the drug might shrink…

This study tested a new approach for people with advanced solid tumors that had stopped responding to standard treatments. First, a laser was used to heat and destroy part of the tumor. Then, a drug called IP-001 was injected directly into the treated area to help the body's immu…

This study tested a new drug called MK-1200 in 13 people with advanced solid tumors, including stomach, esophageal, bile duct, and pancreatic cancers. The goal was to find a safe dose and see if the drug can shrink tumors. Participants had already tried other treatments without s…

This early-stage study tested a new drug called ABBV-155, alone or with standard chemotherapy (paclitaxel or docetaxel), in 168 adults with advanced solid tumors that had stopped responding to treatment. The goal was to find safe doses and see if the drug could shrink tumors. The…

This study offers continued access to the drug tazemetostat for 58 people with certain cancers who previously benefited from it in other trials. The main goal is to track long-term safety and how long participants stay on the drug. It is not a cure but helps control the disease.

This early-stage study tested a new drug called BAT6026 in 30 people with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check the drug's safety, find the best dose, and see if it shows any signs of shrinking tumors. The study is …

This early-stage trial tested an experimental pill called ASC61 in 18 adults with advanced solid tumors that had stopped responding to standard treatments or had no standard options. The goal was to check the drug's safety, find the right dose, and see if it could shrink tumors. …

This early-stage study tested a new drug called AMG 256 in 34 adults with advanced solid tumors that had not responded to standard treatments. The main goal was to check the drug's safety and find the best dose for future studies. The study is now complete, but it does not offer …

This early-stage study tested a new treatment called Anti-ALPP CAR-T cells in 5 people with advanced solid tumors that had not responded to standard therapies. The treatment uses a patient's own immune cells, modified to attack a protein (ALPP) found on certain cancer cells. The …

This study tested a combination of two drugs, lenvatinib and pembrolizumab, in 611 people with advanced cancers that had stopped responding to standard treatments. The cancers included triple-negative breast, ovarian, gastric, colorectal, glioblastoma, biliary tract, and pancreat…

This early-phase study tested a new drug called KL340399, which is injected directly into tumors. It involved 6 adults with advanced solid tumors who had no other treatment options. The main goal was to check safety and find the right dose, not to cure the cancer.

This early-stage study tested a fixed-dose combination of two immunotherapy drugs, relatlimab and nivolumab, in 24 Chinese patients with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety, how the drugs move through the b…

This early-phase study tested a new drug called BAT8006 in 216 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check the drug's safety, find the highest safe dose, and determine the best dose for future studies. Partici…

This study tested a new drug called BMS-986408, given alone or with other cancer drugs (nivolumab and ipilimumab), in 68 people with advanced solid tumors that had not responded to other treatments. The main goal was to check safety and find the best dose. This is an early-stage …

This early-phase study tested a new drug called KL340399 in 21 adults with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check the drug's safety and find the best dose for future studies. Researchers also looked for signs that the …

This early-phase study tested a new drug called AMG 305 in 37 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check the drug's safety and find the best dose for future studies. Participants received the drug and were mo…

This early-stage study tested a new drug called ZGGS15 in 22 adults with advanced solid tumors that no longer respond to standard treatments. The main goals were to find a safe dose and check for side effects. Researchers also looked for signs that the drug might shrink tumors.

This early-phase study tested a new drug called RO7623066, given alone or with other treatments, in 116 adults with advanced solid tumors that had not responded to prior therapies. The main goal was to find the safest dose and check for side effects. Researchers also looked for s…

This early-phase study tested a new drug called NOV140101 in 32 adults with advanced solid tumors that had spread or could not be removed. The main goals were to find the safest dose and check for side effects. Researchers also looked at how the drug moves through the body and wh…

This early-stage study tested a new drug called IBI334 in 28 adults with advanced solid tumors that could not be removed by surgery. The main goals were to check the drug's safety, determine the right dose, and see if it showed any signs of helping shrink tumors. Researchers meas…

This study looked at how the antifungal drug itraconazole changes the way the body processes the cancer drug lurbinectedin. Fourteen adults with advanced solid tumors that had no standard treatment took part. The goal was to measure drug levels in the blood to understand the inte…

This study looked at people with advanced solid tumors (like lung, bladder, or skin cancer) who had been on immunotherapy (PD-1/PD-L1 inhibitors) for one year and whose disease was stable. It randomly assigned them to either stop treatment or continue until their cancer got worse…